Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GILD

3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains

GILD, AMAT, and QCOM all stand out for their capacity to generate cash flow, which allows them to increase value to shareholders through dividends and buybacks.

MarketBeat

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

MarketBeat

3 Cash-Rich Stocks With High Growth Potential Right Now

Discover three high free cash flow yield stocks—Salesforce, Applied Materials, and Gilead Sciences—offering stability and long-term growth potential

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.

Benzinga

Is Wall Street Bullish or Bearish on Gilead Sciences Stock?

Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.

Barchart

What to Expect From Gilead Sciences' Next Quarterly Earnings Report

Gilead Sciences will release its third-quarter earnings later this month, and analysts anticipate a single-digit bottom-line growth.

Barchart

Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences, Inc. (NASDAQ:GILD) as his final trade.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Gilead Reaches Settlement To Block Biktarvy Generics Until 2036

Gilead Sciences, Inc. (NASDAQ:GILD) on Monday entered into settlement agreements to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration to market generic versions of Biktarvy.

Benzinga

Biotech Sector May Flip to Market Leader by Year-End

As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.

MarketBeat

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has significantly outperformed the Nasdaq Composite over the past year, and analysts remain strongly bullish on the stock’s prospects.

Barchart

Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences

While all publicly traded enterprises aim for business success, achieving it can also ironically lead to valuation pressures. That's the tough lesson that pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) learned the hard way recently. Although the company delivered the goods for its latest financial disclosure, post-earnings digestion appears to have…

Benzinga

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy

As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding capabilities and integrating advanced therapeutic platforms. Kite Pharma, a Gilead Sciences Inc. company (NASDAQ:GILD) on Thursday agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR…

Benzinga

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans.

Benzinga

The Saturday Spread: These 3 Stocks Statistically May Be Cooking Up Something Special (GILD, WMB, XPEV)

Forget interpreting financial data and news items. If you want real edge, you’ve got to consider the metrics the market isn’t paying attention to.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.

Benzinga

How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings results for the second quarter, after the closing bell on Thursday, Aug. 7.

Barchart

Are Wall Street Analysts Bullish on Gilead Sciences Stock?

Gilead Sciences has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Benzinga

Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales

In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people who need or…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Barchart

What to Expect From Gilead Sciences’ Q2 2025 Earnings Report

Gilead Sciences is expected to announce its fiscal second-quarter earnings next month, and analysts forecast a single-digit drop in its earnings.

Barchart

The Saturday Spread: Data-Driven Trades That Cut Through the Noise (GILD, MCD, DJT)

This weekend’s edition identifies three hot stocks that are flashing above-average upside probabilities with compelling multi-leg options strategies.

Barchart

Is Gilead Sciences Stock Outperforming the S&P 500?

While Gilead Sciences has outperformed the S&P 500 Index over the past year, analysts are cautiously optimistic about the stock’s prospects.

Barchart

Unusual Options Alert: The Smart Money is Piling Into Gilead Sciences (GILD)

While the new political paradigm might not be the most conducive environment for Gilead Sciences, positive sentiment is brewing for GILD stock.

Barchart

What Are Wall Street Analysts' Target Price for Gilead Sciences Stock?

Gilead Sciences has considerably outpaced the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

MarketBeat

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

1 2 3 4 5

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

328,384 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.